Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours

(2019) Ezequiel Monferrer et al.   BMC CANCER

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

(2019) Liam Cornell et al.   Cell Reports

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

(2019) Luigi Formisano et al.   Nature Communications

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

(2019) Shuo Qie et al.   Nature Communications

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary

(2019) Yibo Xue et al.   Nature Communications

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

(2019) Yibo Xue et al.   Nature Communications

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

(2019) Erik S. Knudsen et al.   ONCOGENE

Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors

(2019) Sarat Chandarlapaty et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer

(2019) Nicole M. Kettner et al.   CLINICAL CANCER RESEARCH

P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy

(2019) D.M. Fernández-Aroca et al.   CANCER LETTERS

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells

(2018) Ahrum Min et al.   CANCER LETTERS

Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma

(2018) Inan Olmez et al.   CANCER RESEARCH

ER+Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

(2018) Angel L. Guerrero-Zotano et al.   CLINICAL CANCER RESEARCH

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

(2018) Renée de Leeuw et al.   CLINICAL CANCER RESEARCH

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

(2018) Chrysiis Michaloglou et al.   MOLECULAR CANCER THERAPEUTICS

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

(2018) Gabriele Romano et al.   Cancer Discovery

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer

(2018) Eric Haines et al.   Oncotarget

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer

(2018) Fan Li et al.   CLINICAL CANCER RESEARCH

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

(2018) Xin Jin et al.   MOLECULAR CELL

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition

(2017) Míriam Tarrado‐Castellarnau et al.   Molecular Systems Biology

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

(2017) S-H Chen et al.   ONCOGENE

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

(2015) M. E. Olanich et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers

(2014) A. M. Heilmann et al.   CANCER RESEARCH

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

(2014) Guoyan Liu et al.   JOURNAL OF PATHOLOGY

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Suppression of tumorigenicity by MicroRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme

(2013) Shuwei Qiu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit

(2013) Sabrina L. Spencer et al.   CELL

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

(2013) Mark A. Dickson et al.   JOURNAL OF CLINICAL ONCOLOGY

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

(2012) L. Cen et al.   NEURO-ONCOLOGY

The meaning of p16ink4aexpression in tumors

(2011) Agnieszka K. Witkiewicz et al.   CELL CYCLE

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

MicroRNA miR-302 Inhibits the Tumorigenecity of Human Pluripotent Stem Cells by Coordinate Suppression of the CDK2 and CDK4/6 Cell Cycle Pathways

(2010) S.-L. Lin et al.   CANCER RESEARCH

Cooperativity ofCdk4R24CandRasin melanoma development

(2010) Rachna Chawla et al.   CELL CYCLE

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE